James Crowe

A monoclonal antibody against the chikungunya virus developed by researchers at Vanderbilt University Medical Center is the first monoclonal antibody encoded by messenger RNA to enter a clinical trial. Read More

Using sophisticated gene sequencing and computing techniques, Vanderbilt researchers have achieved a first-of-its-kind glimpse into how the body’s immune system gears up to fight off infection. Read More

James Crowe Jr. and colleagues have developed a new computational method that may allow researchers to develop flu antibodies that can protect against more strains of the disease. Read More

Scientists at Vanderbilt University Medical Center and colleagues in Boston, Seattle and St. Louis are racing to develop — in a mere 90 days — a protective antibody-based treatment that can stop the spread of the Zika virus. Read More

Brian Engelhardt is studying why as many as 50 percent of stem cell transplant recipients develop diabetes. Read More

Research led by James Crowe, Jr., could lead to the first effective treatment for this dangerous mosquito-transmitted infection. Read More

The discovery of these antibodies could significantly improve the diagnosis and treatment of the leading cause of stomach illness in the world. Read More

A new Vanderbilt study suggests it may be possible to develop antibody therapies or a universal vaccine effective against multiple Ebola virus family members. Read More

Targeting the protein that mosquito-borne viruses use to enter cells could be a strategy for preventing infection by multiple emerging viruses. Read More

Newly discovered features in an RSV protein may be useful for rational structure-based vaccine design. Read More

From Vanderbilt Magazine: James Crowe, director of the Vanderbilt Vaccine Center, hopes to create a universal flu vaccine--permanently eliminating the problem of ineffective or under-effective annual flu shots. Read More

A renowned microbiologist and Ann Scott Carell Professor, Crowe is leading efforts to decipher the human immunome, a vast set of genes and molecular structures critical to fighting disease. Understanding those mechanics could lead to the development of a universal flu vaccine. No guessing required. Read More

James Crowe Jr., M.D., director of the Vanderbilt Vaccine Center, is the 2017 recipient of the Stanley J. Korsmeyer Award given by the American Society for Clinical Investigation (ASCI), one of the nation’s oldest and most respected honor societies for physician-scientists. Read More

Respiratory syncytial virus (RSV) is the major cause of life-threatening viral pneumonia in infants worldwide, yet despite repeated efforts, scientists have been unable to develop an effective vaccine against it. Read More

New discoveries will guide efforts to develop vaccines or antiviral agents for norovirus, the most common cause of infectious diarrhea. Read More

In the latest VUCast: Hear from Ebola survivors helping a Vanderbilt researcher fight the deadly virus; see the high-tech way an art exhibit is bringing VU students face to face with people across the world; and find out which country music star shot his latest video with Mr. Commodore! Watch now. Read More

Vanderbilt researchers have received a five-year, $9 million grant from the National Institutes of Health to design more effective flu vaccines and novel antibody therapies. Read More

U.S. Sen. Lamar Alexander, BA’62, discussed the Ebola epidemic with Vanderbilt physicians during a September visit to campus. Read More